

International Colloquium on Cardio-Oncology

Rome (Italy), March 12-14, 2014

Organized by

DEPARTMENT OF DRUG SCIENCES
AND CLINICAL PHARMACOLOGY
UNIVERSITY CAMPUS BIO-MEDICO OF ROME

Promoted by



FONDAZIONE
INTERNAZIONALE
MENARINI

FINAL PROGRAM

Hotel Columbus
Via della Conciliazione, 33

International Colloquium on Cardio-Oncology

Rome (Italy), March 12-14, 2014

Organized by

DEPARTMENT OF DRUG SCIENCES
AND CLINICAL PHARMACOLOGY
UNIVERSITY CAMPUS BIO-MEDICO OF ROME

Promoted by



FONDAZIONE
INTERNAZIONALE
MENARINI

FINAL PROGRAM

Hotel Columbus
Via della Conciliazione, 33

Dear Colleagues,

It is my great pleasure to introduce you to the International Colloquium on Cardio-Oncology, Rome, March 12-14, 2014.

Cardio-Oncology is a relatively new discipline that cares of the cardiovascular performance of patients treated with anticancer therapies. As any other newborn discipline, Cardio-Oncology struggles to define its scientific boundaries and to identify evidence-based culprits of risk assessment, risk benefit, diagnosis, opportunities for prevention or treatment. This International Colloquium aims to focus on established facts and new ideas that could make easier and clearer to identify the future of Cardio-Oncology in the scientific scenario.

Why a Colloquium instead of a Conference or Workshop? We like Colloquium better than other labels as "Colloquium" conveys the sense of informal interaction we wish to confer on this event.

Moreover, this "Colloquium" aims to embrace contributions from different kind of disciplines (oncology and cardiology but also pediatrics, geriatrics, genetics, translational research). Cardio-oncology goes way beyond cardiology plus oncology.

The Program is self explanatory. It does not review cardiovascular toxicity from one drug or the other, but it looks at patients as we see them in their fight against cancer and eventually going back to everyday life. This is the melting pot in which anticancer therapies and individual or environmental risk factors conspire in producing cardiovascular sequelae.

We thank Menarini International Foundation for promoting this Colloquium and for choosing a Renaissance venue like the Columbus Hotel in Rome. We look forward to seeing you there for a productive and enjoyable Colloquium on Cardio-Oncology.

*Giorgio Minotti
Chair*

*Joseph Carver and Steven Lipshultz
Co-Chairs*

With the Patronage of

Associazione Italiana Oncologia Medica (AIOM)
Società Italiana di Ematologia (SIE)
Società Italiana di Farmacologia (SIF)
International Cardio Oncology Society (ICOS)



The application for European accreditation has been granted 11 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME)

Chair of the Meeting

Giorgio Minotti

University Campus Bio-Medico
Rome, Italy

Co-Chairs of the Meeting

Joseph R. Carver

University of Pennsylvania
and Abramson Cancer Center
Philadelphia (PA - USA)

Steven E. Lipshultz

University of Miami
Miller School of Medicine
Miami (FL - USA)
Wayne State University
Department of Pediatrics and
DMC Children's Hospital of Michigan
Detroit (MI - USA)

Scientific Secretariat

Giorgio Minotti Joseph R. Carver Steven E. Lipshultz

Organizing Secretariat - Provider

AVEC S.r.l. - Incentive Paintings - Angela Volpe / Claudia Cislaghi
Via Laboratori Autobianchi, 1 - c/o Polo Tecnologico Brianza
Edificio 9 - Ufficio 14 - I-20832 Desio (MB), Italy
Phone: +39 0362 581579 – Fax: +39 0362 544211
E-mail: angela.volpe@avec-eventi.com / claudia.cislaghi@avec-eventi.com

Promoted by

Fondazione Internazionale Menarini
Via W. Tobagi, 8
I-20068 Peschiera Borromeo (Milan, Italy)
Phone: +39 02 55308110
Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
Http:\www.fondazione-menarini.it

Wednesday, March 12, 2014 - Afternoon

- 3.00 p.m. - 3.10 p.m. **G. Minotti** (Rome, I)
Welcome address
Structure and goals of this International Colloquium
- 3.10 p.m. - 5.30 p.m. *Session I - What is cardiotoxicity?***
- Chairs: **G. Minotti** (Rome, I)
E.T. Yeh (Houston, TX - USA)
- 3.10 p.m. - 3.40 p.m. **T.L. Force** (Philadelphia, PA - USA)
Defining cardiotoxicity in preclinical models:
strengths and weaknesses
- 3.40 p.m. - 3.50 p.m. Discussion
- 3.50 p.m. - 4.20 p.m. **S.D. Colan** (Boston, MA - USA)
Defining cardiovascular liability of antitumor drugs
in patients: What is the level of evidence?
- 4.20 p.m. - 4.30 p.m. Discussion
- 4.30 p.m. - 5.30 p.m. Panel Discussion and Summary Statements
- 5.30 p.m. - 6.30 p.m. Welcome ceremony

8.30 a.m. – 10.30 a.m. Session II - Cardiotoxicity in children, adolescents and young adults

Chairs: **S.E. Lipshultz** (Miami, FL - Detroit, MI - USA)
R.K. Steiner (Zurich, CH)

8.30 a.m. - 9.00 a.m. **S.E. Lipshultz** (Miami, FL - USA)
Pathophysiology, clinical course, and protection

9.00 a.m. - 9.10 a.m. Discussion

9.10 a.m. - 9.40 a.m. **G.T. Armstrong** (Memphis, TN - USA)
Late cardiotoxicity in survivors: Role of chronic health conditions

9.40 a.m. - 9.50 a.m. Discussion

9.50 a.m. - 10.20 a.m. **F.E. van Leeuwen** (Amsterdam, NL)
Long-term risk of various cardiovascular diseases after different cancer treatments in adolescents and young adults

10.20 a.m. - 10.30 a.m. Discussion

10.30 a.m. - 11.00 a.m. *Coffee break*

11.00 a.m. - 1.30 p.m. Session III - Cardiotoxicity in adults

Chairs: **M. Ewer** (Houston, TX - USA)
L. Gianni (Milan, I)

11.00 a.m. - 11.30 a.m. **T.M. Suter** (Bern, CH)
How we measure cardiotoxicity in clinical trials and how we see it in the general population

11.30 a.m. - 11.40 a.m. Discussion

11.40 a.m. - 12.10 p.m. **D.J. Lenihan** (Nashville, TN - USA)
Oncologic efficacy vs cardiotoxicity:
Risk: benefit and cardiac prevention issues

12.10 p.m. - 12.20 p.m. Discussion

12.20 p.m. - 01.30 p.m. Panel Discussion and Summary Statements

01.30 p.m. - 02.30 p.m. *Buffet lunch*

2.30 p.m. - 6.00 p.m. *Session IV - Cardiotoxicity in special populations*

Chairs: **J.R. Carver** (Philadelphia, PA - USA)
 F. Pane (Naples, I)

2.30 p.m. - 2.55 p.m. **J.R. Carver** (Philadelphia, PA - USA)
 Older patients

2.55 p.m. - 3.00 p.m. Discussion

3.00 p.m. - 3.25 p.m. **D.B. Sawyer** (Nashville, TN - USA)
 Patients with preexisting cardiovascular disease

3.25 p.m. - 3.30 p.m. Discussion

3.30 p.m. - 4.00 p.m. *Coffee break*

4.00 p.m. - 4.25 p.m. **C. Cipolla** (Milan, I)
 Patients with prior chemotherapy

4.25 p.m. - 4.30 p.m. Discussion

4.30 p.m. - 4.55 p.m. **S.C. Darby** (Oxford, UK)
 Radiotherapy patients

4.55 p.m. - 5.00 p.m. Discussion

5.00 p.m. - 6.00 p.m. Panel Discussion and Summary Statements

Friday, March 14, 2014 - Morning

Session V - The future of cardio-oncology

8.30 a.m. – 10.30 p.m. I. Networking and databases

Chairs: **J.R. Carver** (Philadelphia, PA - USA)
S.E. Lipshultz (Miami, FL - Detroit, MI - USA)
G. Minotti (Rome, I)

8.30 a.m. - 9.00 a.m. **S. Sallan** (Boston, MA - USA)
ONCO-cardiology: Horse before cart.
Lessons from the long-term follow-up
of survivors of childhood cancer

9.00 a.m. - 9.10 a.m. Discussion

9.10 a.m. - 9.40 a.m. **S.M. Swain** (Washington, DC - USA)
Can the childhood cancer survivor model
be extended to adults?

9.40 a.m. - 9.50 a.m. Discussion

9.50 a.m. - 10.30 a.m. Panel Discussion and Summary Statements

10.30 a.m. - 11.00 a.m. *Coffee break*

continue

Friday, March 14, 2014 - Morning

11.00 a.m. - 01.30 p.m. II. Identifying at-risk patients

- Chairs: **M.T. Sandri** (Milan, I)
L. Wojnowski (Mainz, D)
- 11.00 a.m. - 11.30 p.m. **L.C.M. Kremer** (Amsterdam, NL)
Before therapy: genotyping and the level
of evidence
- 11.30 a.m. - 11.40 a.m. Discussion
- 11.40 a.m. - 12.10 p.m. **D. Cardinale** (Milan, I)
During therapy: Biomarkers and the many doubts
- 12.10 p.m. - 12.20 p.m. Discussion
- 12.20 p.m. - 01.10 p.m. Panel Discussion and Summary Statements
- 01.10 p.m. **G. Minotti** (Rome, I)
Closing of the Colloquium: Did we meet our
goals?
- 01.30 p.m. *Buffet lunch*

GENERAL INFORMATION

Meeting venue

The Congress will take place at Hotel Columbus, Via della Conciliazione 33, I-00193 Rome (Italy).

Secretariat during the Meeting

Opening hours:

Wednesday, March 12, from 2.30 p.m. to 6.30 p.m.

Thursday, March 13, from 8.00 a.m. to 6.00 p.m.

Friday, March 14, from 8.00 a.m. to 1.30 p.m.

Official language

The official language of the Meeting will be English. Simultaneous translation will not be provided.

CME Accreditation

The application for CME accreditation has been submitted with 10,5 credits (Cardiology, Oncology, Hematology, Internal Medicine, Epidemiology, Genetics, Radiotherapy, Pediatrics, Geriatrics, Biology).

The CME credits will be awarded only after full attendance of all sessions. Completion of the Registration Form, the Learning & Assessment questionnaires are compulsory.

European Accreditation

An application has been made to the EACCME for CME accreditation of this event.

The application for European accreditation has been granted 11 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Technical facilities

Facilities will be available for computer presentations and overhead projections.

A business center with PC (Windows and MAC) will be available to check and preview presentations. Speakers are required to give a copy of their presentation on USB memory stick, CD or DVD to the technicians at the Slide Center at least one hour before the session.

Opening hours of the Slide Center:

Wednesday, March 12, from 2.30 p.m. to 6.30 p.m.

Thursday, March 13, from 8.00 a.m. to 6.00 p.m.

Friday, March 14, from 8.00 a.m. to 1.30 p.m.

Lunches and coffee breaks

Buffet lunches and coffee breaks will be served in the Meeting area.

Abstracts book

Participants will receive the Abstract book at the Meeting.

Certificate of attendance

Certificates of Attendance will be issued at the registration desk following full attendance of the Symposium.

Registration

Symposium attendance is free of charge. Please return the registration form to:

AVEC S.r.l. - Incentive Paintings - Angela Volpe / Claudia Cislighi

Via Lavoratori Autobianchi, 1 - c/o Polo Tecnologico Brianza - Edificio 9 - Ufficio 14 - I-20832 Desio (MB), Italy

Phone: +39 0362 581579 – Fax: +39 0362 544211

E-mail: angela.volpe@avec-eventi.com / claudia.cislighi@avec-eventi.com

FACULTY

Gregory T. Armstrong, MD

St. Jude Children's Research Hospital
Memphis (TN - USA)

Daniela Cardinale, MD

European Institute of Oncology
Milan (Italy)

Joseph R. Carver, MD

University of Pennsylvania and Abramson Cancer Center
Philadelphia (PA - USA)

Carlo Cipolla, MD

European Institute of Oncology
Milan (Italy)

Steven D. Colan, MD

Harvard Medical School
Boston (MA - USA)

Sarah C. Darby, PhD

University of Oxford
Oxford (UK)

Michael Ewer, MD

The University of Texas MD Anderson Cancer Center
Houston (TX - USA)

Thomas L. Force, MD

Temple University School of Medicine
Philadelphia (PA - USA)

Luca Gianni, MD

Hospital San Raffaele
Milan (Italy)

Leontien C.M. Kremer, MD

Emma Children's Hospital-Academic Medical Center
Amsterdam (The Netherlands)

Daniel J. Lenihan, MD

Vanderbilt University School of Medicine
Nashville (TN - USA)

Michael P. Link, MD
Stanford University School of Medicine
Palo Alto (CA - USA)

Steven E. Lipshultz, MD
University of Miami Miller School of Medicine
Miami (FL - USA)
Wayne State University Department of Pediatrics and
DMC Children's Hospital of Michigan
Detroit (MI - USA)

Giorgio Minotti, MD
University Campus Bio-Medico
Rome (Italy)

Fabrizio Pane, MD
Policlinico Federico II
Naples (Italy)

Stephen Sallan MD tll
Dana-Farber Cancer Institute
Boston (MA-USA)

Maria Teresa Sandri, MD
European Institute of Oncology
Milan (Italy)

Douglas B. Sawyer, MD
Vanderbilt University School of Medicine
Nashville (TN - USA)

Rudolf K. Steiner, MD
Zurich University
Zurich (Switzerland)

Thomas M. Suter, MD
Bern University Hospital
Bern (Switzerland)

Sandra M. Swain, MD
Washington Cancer Institute
Washington (DC - USA)

Flora E. van Leeuwen, PhD
Netherlands Cancer Institute
Amsterdam (The Netherlands)
Leszek Wojnowski, MD
University Mainz
Mainz (Germany)

Edward T. Yeh, MD
The University of Texas MD Anderson Cancer Center
Houston (TX - USA)

A special thank to

Celgene Italia
Cell Therapeutics
Janssen Cilag
Takeda Italia
Teva Italia S

for not conditioning financial support

